Editorial: ICRF-187 As a Cardioprotectant in Children Treated with Anthracyclines

Pediatric Hematology and Oncology

Volumn 14, Issue 3, 1997, Pages iii-vi

  Blatt, Julie ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

anthracyclines; cardiotoxicity; childhood; ICRF 187

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; RAZOXANE;

CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHILDHOOD CANCER; DRUG EFFECT; DRUG SCREENING; EDITORIAL; HEART PROTECTION; HUMAN;

ANTHRACYCLINES; CARDIOVASCULAR AGENTS; CHILD; FEMALE; HEART; HUMANS; INFANT; MALE; RAZOXANE;

EID: 0030921949     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880019709009486     Document Type: Editorial

References (13)

1. Truesrlell S, Schwartz C L., Clark E, Constine L S. Cardiovascular effects of cancer therapy. Survivors of Childhood Cancer: Assessment and Management, C L. Schwartz, et al. Mosby, St Louis 1994; 159 – 176
2. Schiavetti A, Castello M A., Versacci P, et al. Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results. Pediatr Hematol Oncol 1997; 14: 213 – 222
3. Herman E H., Ferrans V J., Jordan W, et al. Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res Commun Chemother Pathol Pharmacol 1981; 31: 85 – 97
4. Herman E H., Ferrans V J. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187). Cancer Res 1981; 41: 3436 – 3440
5. Speyer J L., Green M D., Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745 – 752
6. Wexler L H., Andrick M P., Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14: 362 – 372
7. Holcenbcrg J S., Tutsch K D., Earhart R H., et al. Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treat Rev 1986; 70: 703 – 709
8. Vats T, Kamen B, Krischer J P. Phase II trial of ICRF-187 in children with solid tumors and acute leukemia. Invest New Drugs 1991; 9: 333 – 337
9. Dexrazoxane for cardiac protection against doxorubicin. Med Lett 1995; 37: 110 – 111
10. Woodman R J. Enhancement of antitumor effectiveness of ICRF-159 against early L1210 leukemia by combination with cis-diamminodichloroplatinum or daunomycin. Cancer Chemother Rep 1974; 4: 45 – 52
11. Wadler S, Green M D., Muggia F M. Synergistic activity of doxorubicin and the bisdioxopiperazine (=)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) against the murine sarcoma S180 cell line. Cancer Res 1986; 46: 1176 – 1181
12. Lipshultz S E. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol 1996; 14: 328 – 331
13. Pedersen-Bjergaard J. The dioxopiperazine derivatives, their leukemogenic potential and other biological effects. Leuk Res 1992; 16: 1057 – 1059